ABVX

Abivax SA is a clinical-stage biotechnology company focused on developing therapies that modulate the immune system to treat inflammatory diseases, viral infections, and cancer. Headquartered in Paris, France, the company operates research facilities in France and maintains a presence in the United States. Abivax's lead product candidate, obefazimod (ABX464), is an oral therapy in late-stage clinical development for ulcerative colitis and has shown promise in treating other inflammatory conditions. The compound works by targeting the mir-124 anti-inflammatory pathway, representing a novel mechanism of action in immune modulation. The company also develops ABX196, a checkpoint inhibitor program for oncology applications. Abivax trades on the Euronext Paris stock exchange and maintains a partnership-driven business model, having established collaborations with pharmaceutical companies to advance its pipeline. In recent developments, the company has progressed obefazimod through Phase 2b/3 clinical trials for ulcerative colitis and continues to generate clinical data supporting its therapeutic approach. As a research-focused organization, Abivax does not yet generate product revenue and funds operations through equity financing and strategic partnerships. The company employs approximately 50 people and concentrates its resources on advancing obefazimod toward potential regulatory approval while exploring the platform's applicability across multiple immune-mediated conditions.